Skip to main content

Table 1 Patient characteristics

From: Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis

Patients

 

NLR ≤ 1.9

NLR > 1.9

PLR ≤ 131.2

PLR > 131.2

 

n = 65

n = 33

n = 32

n = 33

n = 32

Male/female

 n

42/23

23/10

19/13

26/7

16/16

 %

64.6/35.4

69.7/30.3

59.4/40.6

78.8/21.2

50.0/50.0

Age, mean years (SD)

51.3 (12.7)

48.1 (11.0)

54.6 (13.4)

51.6 (12.7)

51.0 (12.6)

Asthma n/%

41/63.1

20/62.5

21/70.0

18/58.1

23/74.2

AERD n/%

32/49.2

19/57.6

13/41.9

15/46.9

17/53.1

Prior ESS, mean number (SD)

2.0 (1.5)

2.0 (1.6)

2.1 (1.4)

2.0 (1.6)

2.1 (1.4)

Pretreatment NPS

 Median

4

4

4

1

4

 Min.–max

1–8

1–8

1–8

0–6

1–8

  1. n number of patients, % percentage of patients, AERD aspirin-exacerbated respiratory disease, ESS endoscopic sinus surgery, SD standard deviation, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, min. minimum value, max. maximum value